论文部分内容阅读
为评价肺表面活性剂（ＰＳ）治疗ＲＤＳ和重症肺炎的疗效，本文对１２例接受ＰＳ治疗的新生儿ＲＤＳ和重症肺炎病例进行分析。结果显示：治疗组患儿在病程不同时期的ａ／ＡＰＯ２均明显高于对照组（Ｐ均＜０．０５），肺部并发症的发生率低于对照组，机械通气时间、需氧时间及住院时间均明显短于对照组（Ｐ均＜０．０５）。治疗组患儿的存活率为７５％，对照组为３７％，两组比较，差异显著（Ｐ＜０．０５）。提示：ＰＳ治疗能有效地改善新生儿ＲＤＳ和肺炎患儿的肺氧合功能，减少肺部并发症的发生，缩短病程
To evaluate the efficacy of pulmonary surfactant (PS) in the treatment of RDS and severe pneumonia, 12 cases of neonatal RDS and severe pneumonia treated with PS were analyzed. The results showed that the a / APO2 of the treatment group was significantly higher than that of the control group (P <0.05), the incidence of pulmonary complications was lower than that of the control group, the duration of mechanical ventilation, aerobic time and The length of hospital stay was significantly shorter than that of the control group (all P <0.05). Survival rate was 75% in the treatment group and 37% in the control group, the difference was significant (P <0.05). Tip: PS treatment can effectively improve neonatal RDS and pneumonia in children with pulmonary oxygen function, reduce the incidence of pulmonary complications and shorten the course